Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET])
Brett R. Cowan(University of Auckland), Garry Jennings(The University of Sydney), Salim Yusuf(Population Health Research Institute), Angela Wadham(University of Auckland), Cheuk‐Man Yu(Chinese University of Hong Kong), John E. Sanderson(University of Birmingham), Roland E. Schmieder(Universitätsklinikum Erlangen), Alistair A. Young(King's College - North Carolina), Koon Teo(Population Health Research Institute), Robert N. Doughty(National Heart Foundation of New Zealand), Rungroj Krittayaphong(Siriraj Hospital), Thomas H. Marwick(The University of Queensland), Stephen G. Worthley(Royal Adelaide Hospital), Craig S. Anderson(Royal Prince Alfred Hospital), Chris Reid(Monash University), Eva Lonn(McMaster University)
Cited by 47
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study
|The Lancet|2005|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k